

1 H, 13 C, 15 N NMR Resonance Assignments and Secondary Structure Determination of the Extra-Cellular Domain from the Human Proapoptotic TRAIL-R2 Death Receptor 5 (DR5-ECD)

Antoine Baudin, Anne Guichard, Gavin W Collie, Sabrina Rousseau, Stéphane Chaignepain, Agnès Hocquellet, Mélanie Berbon, Antoine Loquet, Cameron Mackereth, Gilles Guichard, et al.

▶ To cite this version:

Antoine Baudin, Anne Guichard, Gavin W Collie, Sabrina Rousseau, Stéphane Chaignepain, et al.. 1 H, 13 C, 15 N NMR Resonance Assignments and Secondary Structure Determination of the Extra-Cellular Domain from the Human Proapoptotic TRAIL-R2 Death Receptor 5 (DR5-ECD). Biomolecular NMR Assignments, 2018, 12 (2), pp.309-314. 10.1007/s12104-018-9828-1. hal-02349452

HAL Id: hal-02349452 https://hal.science/hal-02349452

Submitted on 5 Nov 2019

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

¹H, ¹³C, ¹⁵N NMR Resonance Assignments and Secondary Structure Determination of the Extra-Cellular Domain from the Human Proapoptotic TRAIL-R2 Death Receptor 5 (DR5-ECD)

Antoine Baudin¹, Anne Guichard^{1,2}, Gavin W. Collie^{1,3,6}, Sabrina Rousseau^{3,5}, Stéphane Chaignepain^{1,4}, Agnès Hocquellet¹, Mélanie Berbon^{1,3}, Antoine Loquet^{1,3}, Cameron Mackereth^{3,5}, Gilles Guichard^{1,3} and Benoît Odaert^{1*}

¹Université de Bordeaux – CNRS – Bordeaux INP, Chimie et Biologie des Membranes et des Nano-objets (CBMN), UMR 5248, Bâtiment B14, Allée Geoffroy Saint Hilaire, 33600 Pessac Cedex, France

²Agenus UK Limited, 315, Science Park, Milton Road, Cambridge, CB4 0WG, United Kingdom

³Institut Européen de Chimie et Biologie, Univ. Bordeaux, 2 rue Robert Escarpit, 33607 Pessac France

⁴Centre de Génomique Fonctionnelle de Bordeaux (CGFB), 146 rue Léo Saignat, 33000 Bordeaux, France

⁵Inserm U1212, CNRS UMR5320, ARNA Laboratory, 146 rue Léo Saignat, 33076 Bordeaux, France

⁶ Discovery Sciences, IMED Biotech Unit, AstraZeneca, Cambridge, UK.

*To whom correspondence should be addressed: Benoît Odaert (<u>b.odaert@cbmn.u-bordeaux.fr</u>) Tel: +33-5-40-00-68-35. Fax: +33-5-40-00-22-00

Abstract

Death Receptors (DR) selectively drive cancer cells to apoptosis upon binding to the Tumor necrosis factor-α-Related Apoptosis-Inducing Ligand (TRAIL). Complex formation induces the oligomerization of the death receptors DR4 (TRAIL-R1) and DR5 (TRAIL-R2) and transduces the apoptogenic signal to their respective Death Domains, leading to Death Inducing Signaling Complex (DISC) formation, caspase activation and ultimately cell death. Several crystal structures of the ExtraCellular Domain from Death Receptor 5 (DR5-ECD) have been reported in complex with the TRAIL ligand or anti-DR5 antibodies, but none for the isolated protein. In order to fill this gap and to perform binding experiments with TRAIL peptidomimetics, we have produced isotopically labelled DR5-ECD and started a conformational analysis by using high-field 3D NMR spectroscopy. Herein, we present the first resonance assignment of a TRAIL receptor in solution and the determination of its secondary structure from NMR chemical shifts.

Abbreviations: DR5 Death Receptor 5; TRAIL Tumor necrosis factor-α-Related Apoptosis-Inducing Ligand; ECD Extra Cellular Domain; HSQC Heteronuclear Single Quantum Coherence transfer.

Keywords: DR5; TRAIL; Cancer; Apoptosis; NMR spectroscopy; Resonance Assignment; Secondary Structure.

Biological context

Tumor necrosis factor- α -Related Apoptosis-Inducing Ligand (TRAIL/Apo2L/TNFSF10) is a type II transmembrane trimeric protein that induces apoptosis of cancer cells while sparing normal ones (Ashkenazi A and Dixit VM, 2008). Four membrane-bound TRAIL specific receptors have been described, comprising two Death Receptors DR5/TNFRSF10B/TRAIL-R2) that mediate (DR4/TNFRSF10A/TRAIL-R1 and the apoptogenic signal and two Decoy Receptors (DcR1/TNFRSF10C/TRAIL-R3 and DcR2/TNFRSF10D/TRAIL-R4) that bind the ligand but do not transduce the apoptogenic signal (MacFarlane M et al, 1997; Walczak H et al, 1997). TRAIL binding induces receptor oligomerization (Ashkenazi A et Dixit VM, 1998), transduction of the apoptogenic signal to the intracellular death domain (DD) of the receptors and DISC formation. Autocleavage of the initiator caspases results in activation of the death-executing caspase cascade. leading to cell death (Ashkenazi A and Dixit VM, 2008; Newsom-Davis T et al, 2009; Takeda K et al, Oncogene 2007; Merino D et al, 2007) Crystal structures of TRAIL

2

complexed with the Extra Cellular Domain (residues 6-135 of our plasmid construct) of DR5 (DR5-ECD) unravel the mechanism for receptor oligomerization (Hymowitz SG et al, 1999: 1DOG.pdb; Mongkolsapaya J et al, 1999: 1D4V.pdb; Cha SS et al, 2000: 1DU3.pdb): The elongated DR5 receptors snuggle into long crevices between pairs of monomers of the homotrimeric TRAIL ligand, but do not interact with each other. The TRAIL/DR5 interface is divided into two distinct patches, one near the bottom of the complex close to the membrane surface (90S loop of DR5) and one near the top (50S loop of DR5). The elongated structure of DR5-ECD is arranged into three Cysteine-Rich Domains (CRD). CRD1 (32-48) adopts a beta hairpin conformation (B1B2) stabilized by the disulphide bridge 33-46 and is preceded by the N-terminal region in a disordered conformation. CRD2 (49-90) and CRD3 (91-135) possess two consecutive beta hairpins (B3-B6 and B7-B10 respectively) stabilized by three disulphide bridges (49-65, 68-81, 71-89 and 91-105, 108-122, 112-130 respectively). The 50S loop (residues S56 to R67) and 90S loop (residues E99 to R109) involved in TRAIL binding display similar conformations despite the absence of any sequence homology. The crystal structure of DR5-ECD has also been solved in complex with the human glycoprotein UL141 (Nemčovičova I et al, 2013: 4I9X.pdb) and with the Fab fragments of five anti-DR5 antibodies (Fellouse FA et al, 2005: 1ZA3.pdb; Li B et al, 2006: 2H9G.pdb; Adams C et al, 2008: 4OD2.pdb; Graves JD et al, 2014: 4N90.pdb; Tamada J et al, 2015: 3X3F.pdb). No structural characterization of the isolated DR5-ECD has yet been reported either by crystallography or NMR spectroscopy.

We report here for the first time the assignment of NMR resonances and the secondary structure determination of a TRAIL Death Receptor in solution, namely DR5/TRAIL-R2. Chemical shift assignment has been used to perform binding studies with TRAILmim peptidomimetics that bind to DR5 (Pavet V et al, 2010; Pulka-Ziach K et al, 2015; Beyrath J et al, 2016) and the results will be reported in a future publication.

Materials and Experiments:

Sample preparation

The DR5 extracellular domain (DR5-ECD) was cloned from a commercial pET23m plasmid containing the DR5 gene (Hye-Ji CHI, 2010) by using PCR amplification. The primers were designed to introduce NcoI and BamHI restriction sites, respectively, in order to insert the gene into a modified pET23-d plasmid containing an N-terminal Histidine₍₆₎- tag followed by *E. coli* NusA protein and a tobacco etch virus (TEV) cleavage site. Correct cloning was confirmed by DNA sequencing. The production of the protein was carried out

by heat-shock transformation of the plasmid in BL21(DE3) E. coli bacteria (New England Biolabs), which were then cultured in 1 L of ¹⁵N/¹³C.¹⁵N enriched minimal M9 medium. containing 1 g/L of ¹³C¹⁵N Isogro® (Sigma Aldrich). Following bacteria growth, protein expression was induced at a bacterial OD_{600nm} of 0.8 with isopropyl β-D-1thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM, for 16 hours at 25 °C. The cells were then harvested by centrifugation and stored at -80°C. All purification steps were carried out with Fast Protein Liquid Chromatography (FPLC) on an AKTA Pure system (GE Healthcare). Cell pellets were thawed and resuspended in lysis buffer (50 mM Tris pH 7.5, 500 mM NaCl, 5 mM imidazole), in the presence of phenylmethylsulfonyl fluoride (PMSF) as a protease inhibitor, followed by cell lysis performed by sonication. Membranes and cell debris were centrifuged, and the supernatant was loaded on a 5 mL HisTrap HP column (GE Healthcare), previously equilibrated with the lysis buffer. The column was then washed with 10 column volumes of washing buffer (50 mM Tris pH 7.5, 500 mM NaCl, imidazole 25mM), and protein was eluted with a 50 mM Tris pH 7.5, 500 mM NaCl, imidazole 300mM buffer. Purity of the sample was enhanced by a step of size exclusion chromatography on a HiLoad 16/600 Superdex 200 prep grade column (GE Healthcare), previously equilibrated with appropriate buffer (20 mM Tris pH 7.8, 50 mM NaCl). TEV protease cleavage was then carried out overnight at room temperature, at a TEV:NusA-DR5 mass ratio of 1:100, after which the protein sample was loaded on a 5 mL HiTrap column (GE Healthcare), pre-equilibrated with the same buffer, for anion exchange chromatography. After elution at a NaCl concentration of 250 mM, the final DR5 protein consisted of 135 residues, including 3 N-ter residues (Gly₁-Ala₂-Met₃) remaining from the TEV cleavage site. Sample purity was checked by SDS-PAGE (15 % gels). All NMR samples were buffer exchanged with 20 mM Na₂HPO₄ pH 6.3 50 mM NaCl and either 10 % or 100 % D₂O, using PD-10 columns (GE Healthcare). ¹³C¹⁵N-DR5 sample concentration was made to 300 µM for assignment, using Amicon Ultra centrifugal 10 kD molecular weight cutoff filter units (Merck).

Mass spectroscopy

The average mass of intact DR5 was measured on a MALDI-TOFTOF mass spectrometer (Ultraflex III, Bruker) used in linear mode with sinapinic acid (Sigma-Aldrich) as a matrix [10 mg/mL solution in 50% acetonitrile in 0.1% aqueous trifluoroacetic acid (TFA)]. The dried droplet method was used for sample loading on a stainless steel target. The instrument was calibrated using an external calibration with a mixture of four standard proteins: Insulin ([M+H]⁺_{average}= 5734.51), Ubiquitin ([M+H]⁺_{average}= 8565.76), Cytochrom C

4

([M+H]⁺_{average}= 12360.97), Myoglobin ([M+H]⁺_{average}= 16952.30) (Bruker). Mass spectrometry (MS) study was performed to measure the average mass of the produced DR5 in order to assess its integrity. This analysis demonstrated the presence of one major form corresponding to an average mass M=14998 Da (mean of four individual analysis). The mass difference between the theoretical mass of the recombinant protein calculated from the sequence (15020.34 Da, taking into account all disulfide bonds in oxydized form) and the experimental mass is in accordance with the mass tolerance accepted for this measurement.

NMR spectroscopy

Spectra were acquired at 303 K on a Bruker Avance III 700 MHz and 800 MHz spectrometers, equipped with a TXI triple resonance probe and cryoprobe, respectively. All data were processed using NMRPipe (Delaglio et al, 1995) and analysed by using CCPNMR analysis 2.4 software (Skinner et al, 2016). Chemical shifts were referenced to TriMethylSilylPropanoic acid (TMSP) inside the samples (Wishart et al., 1995). The ¹H, ¹H α , ¹³C α , ¹H β , ¹³C β and ¹⁵N backbone resonances of DR5-ECD were derived by sequence specific triple resonance 3D NMR spectra, namely HNCO, HN(CA)CO, HNCA, HN(CO)CA, HNCACB, CBCA(CO)NH, HNHA and HBHA(CO)NH. Side-chain resonance assignment was partially achieved by 3D NMR spectra, namely HC(C)H-TOCSY, (H)CCH-TOCSY, H(C)CH-COSY, ¹⁵N-HSQC-NOESY (120 ms mixing time) and ¹⁵N-HSQC-TOCSY (60 ms mixing time), as well as by 2D NMR spectra in 100% D₂O, namely aliphatic and aromatic ¹H¹³C-HSQC, CBHD, CBHE, ¹H¹H-TOCSY and ¹H¹H-NOESY (Sattler et al, 1999).

Extents of assignments and data deposition

Analysis of the 3D sequential NMR experiments allowed us to assign 111 out of the 125 expected ¹⁵N and ¹H backbone resonances (135 residues less 9 prolines and the N-terminal glycine). The backbone assignment is nearly complete (89%), except for 14 residues (A2, Q11, S40, D54, D61, C68, V76, T87, V88, C91, F96, R97, R106, K107). Ten peaks of the ¹H¹⁵N HSQC spectrum however remain unassigned (Figure 1). The presence of additional peaks corresponding to a minor conformation was observed for residues located in the N-terminal flexible region (S5, L7, I8, T9, D12, A14, A20, K24, S26, S27, S29) and for the tryptophan residue W125. Such minor conformations probably result from the surrounding proline residues in a cis conformation (P15, P21, P28 and P124). Slow conformational exchange has also been observed in the loop of the first beta hairpin

(residues 41-44) and may arise from conformational heterogeneity of the disulphide bridge 33-46 or protein oligomerization. We were able to extend the assignment up to 94, 93 and 87% for the CO, Cα and Cβ chemical shifts, respectively. Hα, Cα, Cβ and CO chemical shift values allowed us to assess the secondary structure of the protein in solution by using random coil values (Wang Y and Jardetsky O, 2002) and TALOS-N software (Yang S and Bax A, 2013). We found 8 of the 10 expected strands from crystal structures of DR5 complexes and one additional strand at the N-terminus (Figure 2), namely por portional strand at the N-terminus (Figure 2), namely portional strand at the N 32:33], ß1[37:39], ß2[46:48], ß3[54:55], ß4[69:70], ß5[75:79], ß6[86:91], ß9[116:120] and β10[129:132]. An excellent agreement (Figure 3) has been found for the protein in solution with the X-ray structures of DR5-ECD bound to TRAIL (1DOG.pdb, 1DU3.pdb and 1D4V.pdb), to FAB fragments (1ZA3, 2H9G, 3X3F, 4OD2 and 4N90) and to the glycoprotein UL141 (4I9X.pdb). Most of the resonances for the residues of the third expected β -hairpin β 7[94:96]- β 8[104:106] were not found in the 3D NMR spectra. All the unassigned residues seem to be clustered in the vicinity of the beta sheets (β_1 : residue S40; β3: D54; β4: C68; β5: V76, β6: T87 and V88, β7: F96 and R97; β8: R106 and K107). These residues have not yet been assigned because peaks are missing or are too weak in intensity, probably arising from an excessive linebroadening beyond detection due to the presence of a conformational exchange on the intermediate millisecond timescale. The backbone and side-chain ¹H, ¹³C and ¹⁵N chemical shift values of DR5-ECD have been deposited at BioMagResBank under the accession number 27400.

Acknowledgments

We thank the structural biology platform at the Institut Européen de Chimie et Biologie (UMS 3033) for access to NMR spectrometers and technical assistance. Antoine Baudin was supported by a French PhD fellowship afforded to the University of Bordeaux by the Ministère de la Recherche (MNERT) and a fourth year PhD extension by the Ligue nationale Contre le Cancer (LCC). The project was funded by the Ligue Contre le Cancer de la Gironde. We thank Dr Yong-Sung Kim from the Ajou University of the Republic of Korea for providing us the plasmid containing the gene coding for DR5-ECD. AL and MB acknowledge the H2020 program (ERC-2015-StG GA no. 639020).

References

Adams C, Totpal K, Lawrence D, Marsters S, Pitti R, Yee S, Ross S, Deforge L, Koeppen H, Sagolla M, Compaan D, Lowman H, Hymowitz S, Ashkenazi A (2008). Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5. *Cell Death Differ* 15(5):751-61.

Ashkenazi A and Dixit VM (1998). Death receptors: signaling and modulation. *Science* 281(5381):1305-8.

Beyrath J, Chekkat N, Smulski CR, Lombardo CM, Lechner MC, Seguin C, Decossas M, Spanedda MV, Frisch B, Guichard G, Fournel S (2016). Synthetic ligands of death receptor 5 display a cell-selective agonistic effect at different oligomerization levels. *Oncotarget* 7(40):64942-64956.

Cha SS, Sung BJ, Kim YA, Song YL, Kim HJ, Kim S, Lee MS, Oh BH (2000). Crystal structure of TRAIL-DR5 complex identifies a critical role of the unique frame insertion in conferring recognition specificity. *J. Biol. Chem.* 275(40):31171-7.

Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS (2005). Molecular recognition by a binary code. *J. Mol. Biol.* 348(5):1153-62.

Graves JD, Kordich JJ, Huang TH, Piasecki J, Bush TL, Sullivan T, Foltz IN, Chang W, Douangpanya H, Dang T, O'Neill JW, Mallari R, Zhao X, Branstetter DG, Rossi JM, Long AM, Huang X, Holland PM (2014). Apo2L/TRAIL and the death receptor 5 agonist antibody AMG 655 cooperate to promote receptor clustering and antitumor activity. *Cancer Cell* 26(2):177-89.

Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, Ashkenazi A, de Vos AM (1999). Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. *Mol. Cell* 4(4):563-71.

Li B, Russell SJ, Compaan DM, Totpal K, Marsters SA, Ashkenazi A, Cochran AG, Hymowitz SG, Sidhu SS (2006). Activation of the proapoptotic death receptor DR5 by oligomeric peptide and antiobody agonists. *J. Mol. Biol.* 361(3):522-36.

MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES (1997). Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. *J. Biol. Chem.* 272(41):25417-20.

Mérino D, Lalaoui N, Morizot A, Solary E, Micheau O (2007). TRAIL in cancer therapy: present and future challenges. *Expert Opin Ther Targets* 11(10):1299-34.

Mongkolsapaya J, Grimes JM, Chen N, Xu XN, Stuart DI, Jones EY, Screaton GR (1999). Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. *Nat. Struct. Biol.* 6(11):1048-53.

Nemčovičová I, Benedict CA, Zajonc DM.(2013). Structure of human cytomegalovirus UL141 binding to TRAIL-R2 reveals novel, non-canonical death receptor interactions. *PloS Pathog.* 9(3):e1003224.

Newsom-Davis T, Prieske S, Walczak H (2009). Is TRAIL the holy grail of cancer therapy? *Apoptosis* 14(4):607-23.

Pavet V, Beyrath J, Pardin C, Morizot A, Lechner MC, Briand JP, Wendland M, Maison W, Fournel S, Micheau O, Guichard G, Gronemeyer H (2010). Multivalent DR5 peptides activate the TRAIL death pathway and exert tumoricidal activity. Cancer Res 70(3):1101-10.

Pulka-Ziach K, Pavet V, Chekkat N, Estieu-Gionnet K, Rohac R, Lechner MC, Smulski CR, Zeder-Lutz G, Altschuh D, Gronemeyer H, Fournel S, Odaert B, Guichard G (2015). Thioether analogues of disulfide-bridged cyclic peptides targeting death receptor 5: conformational analysis, dimerisation and consequences for receptor activation. *Chembiochem* 16(2):293-301.

Sattler M, Schleucher J, Griesinger C (1999). Heteronuclear multidimensional NMR experiments for the structure determination of proteins in solution employing pulsed field gradients. *Prog. NMR Spectr.* 34:93–158

Skinner SP, Fogh RH, Boucher W, Ragan TJ, Mureddu LG, Vuister GW (2016). CcpNmr Analysis assign: a flexible platform for integrated NMR analysis. *J. Biomol. NMR* 66:111–124.

Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ (2007). Targeting death-inducing receptors in cancer therapy. *Oncogene* 26(25):3745-57.

Tamada T, Shinmi D, Ikeda M, Yonezawa Y, Kataoka S, Kuroki R, Mori E, Motoki K (2015). TRAIL-R2 Superoligomerization Induced by Human Monoclobal Agonistic Antibody KMTR2. *Sci Rep* 5:17936.

Yang S and Bax A (2013). TALOS-N : Protein backbone and sidechain torsion angles predicted from NMR chemical shifts using artificial neural networks. *J. Biomol. NMR* 56:227-241.

Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, Timour MS, Gerhart MJ, Schooley KA, Smith CA, Goodwin RG, Rauch CT (1997). TRAIL-R2: a novel apoptosismediating receptor for TRAIL. *EMBO J*. 16(17):5386-7.

Wang Y, Jardetzky O (2002). Probability-based protein secondary structure identification using combined NMR chemical-shift data. *Protein Sci.* 11(4):852-61.

Wishart D.S., Bigam C.G., Yao J., Abildgaard F., Dyson H.J., Oldfield E., Markley J.L., Sykes B.D. (1995). 1H, 13C and 15N chemical shift referencing in biomolecular NMR. J. Biomol. NMR 6:135-40.

Figures with titles and legends

Figure 1:

Annotated ¹H-¹⁵N HSQC spectrum of DR5-ECD

The spectrum was acquired at 303K on a Bruker Avance III 800 MHz spectrometer equipped with a 5 mm TXI ${}^{1}H/{}^{13}C/{}^{15}N/{}^{2}H$ cryoprobe. The ${}^{15}N{}^{13}C$ labelled protein was at a concentration of 300 μ M in 20 mM Na $_{2}HPO_{4}$ pH 6.3 50 mM NaCl in a mixture of 90% H₂O/ 10% D₂O. The assignment of the peaks is indicated with the amino acid letter followed by the residue number. For clarity, a more detailed view of the central region is displayed separately in the top left corner of the spectrum. Unassigned peaks are labelled by the letters na. Assigned peaks corresponding to the major (65%) and minor (35%) conformations for the same residue are respectively colored in black and cyan.

Figure 2:

Secondary structure of DR5-ECD in solution

Assignment of secondary structure results from the TALOS prediction based on the backbone resonance values. Chemical Shift Indexes (CSI) are calculated with chemical shift values of ${}^{13}C\alpha$, ${}^{13}C\beta$, ${}^{13}CO$ and ${}^{1}H\alpha$ resonances. The ten strands of the consecutive five beta hairpins are sequentially annotated by the letter beta followed by the corresponding number.

Figure 3:

Comparison of DR5-ECD secondary structures in crystals and in solution

Alignment of the DR5-ECD protein sequences used in crystallography and NMR spectroscopy. Crystal structures of the DR5 bound to TRAIL or Fab fragments of anti-DR5 antibodies are indicated on the left of the figure with the pdb code and the subunit. Visible and missing residues are respectively in black and in grey. Residues in the beta conformation are in blue. Disulphide bridges are indicated. The three Cysteine Rich Domains (CRD) are represented schematically by rectangles in different colors.



Figure 1





Figure 3